Photodynamic therapy (PDT) with endoscopic ultrasound for the treatment of esophageal cancer

Timothy A. Woodward, Herbert C. Wolfsen

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

In 1995, PDT was approved for palliative use in patients with esophageal cancer. We report our experience using PDT to treat esophageal cancer patients previously treated with combination chemotherapy and radiation therapy. In our series, nine patients referred for PDT with persistent esophageal cancer after chemo-radiation therapy. We found: (1) All patients were men with a mean age of 63 years and eight out of nine had adenocarcinoma with Barrett's esophagus; (2) All patients required endoscopic dilation after PDT; (3) At a mean follow up of 4 months, two T2N0 patients had no demonstrable tumor and all three T3N0 patients had >50% tumor reduction (the partially responsive T3N0 patients will be offered repeat PDT); (4) Patients with metastatic disease (T3N1 or M1) had effective dysphagia palliation. Thus, PDT is safe and effective in ablating all or most tumor in patients with persistent esophageal cancer after chemotherapy and radiation therapy.

Original languageEnglish (US)
Title of host publicationProceedings of SPIE - The International Society for Optical Engineering
PublisherSociety of Photo-Optical Instrumentation Engineers
Pages422-425
Number of pages4
Volume3907
StatePublished - 2000
EventLasers in Surgery: Advanced Characterization, Therapeutics, and Systems X - San Jose, CA, USA
Duration: Jan 22 2000Jan 25 2000

Other

OtherLasers in Surgery: Advanced Characterization, Therapeutics, and Systems X
CitySan Jose, CA, USA
Period1/22/001/25/00

Fingerprint

Photodynamic therapy
therapy
Ultrasonics
cancer
Radiotherapy
Tumors
Chemotherapy
radiation therapy
tumors
chemotherapy
esophagus

ASJC Scopus subject areas

  • Electrical and Electronic Engineering
  • Condensed Matter Physics

Cite this

Woodward, T. A., & Wolfsen, H. C. (2000). Photodynamic therapy (PDT) with endoscopic ultrasound for the treatment of esophageal cancer. In Proceedings of SPIE - The International Society for Optical Engineering (Vol. 3907, pp. 422-425). Society of Photo-Optical Instrumentation Engineers.

Photodynamic therapy (PDT) with endoscopic ultrasound for the treatment of esophageal cancer. / Woodward, Timothy A.; Wolfsen, Herbert C.

Proceedings of SPIE - The International Society for Optical Engineering. Vol. 3907 Society of Photo-Optical Instrumentation Engineers, 2000. p. 422-425.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Woodward, TA & Wolfsen, HC 2000, Photodynamic therapy (PDT) with endoscopic ultrasound for the treatment of esophageal cancer. in Proceedings of SPIE - The International Society for Optical Engineering. vol. 3907, Society of Photo-Optical Instrumentation Engineers, pp. 422-425, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems X, San Jose, CA, USA, 1/22/00.
Woodward TA, Wolfsen HC. Photodynamic therapy (PDT) with endoscopic ultrasound for the treatment of esophageal cancer. In Proceedings of SPIE - The International Society for Optical Engineering. Vol. 3907. Society of Photo-Optical Instrumentation Engineers. 2000. p. 422-425
Woodward, Timothy A. ; Wolfsen, Herbert C. / Photodynamic therapy (PDT) with endoscopic ultrasound for the treatment of esophageal cancer. Proceedings of SPIE - The International Society for Optical Engineering. Vol. 3907 Society of Photo-Optical Instrumentation Engineers, 2000. pp. 422-425
@inproceedings{b05a373c9eaa4a03a0fadba2aca752f5,
title = "Photodynamic therapy (PDT) with endoscopic ultrasound for the treatment of esophageal cancer",
abstract = "In 1995, PDT was approved for palliative use in patients with esophageal cancer. We report our experience using PDT to treat esophageal cancer patients previously treated with combination chemotherapy and radiation therapy. In our series, nine patients referred for PDT with persistent esophageal cancer after chemo-radiation therapy. We found: (1) All patients were men with a mean age of 63 years and eight out of nine had adenocarcinoma with Barrett's esophagus; (2) All patients required endoscopic dilation after PDT; (3) At a mean follow up of 4 months, two T2N0 patients had no demonstrable tumor and all three T3N0 patients had >50{\%} tumor reduction (the partially responsive T3N0 patients will be offered repeat PDT); (4) Patients with metastatic disease (T3N1 or M1) had effective dysphagia palliation. Thus, PDT is safe and effective in ablating all or most tumor in patients with persistent esophageal cancer after chemotherapy and radiation therapy.",
author = "Woodward, {Timothy A.} and Wolfsen, {Herbert C.}",
year = "2000",
language = "English (US)",
volume = "3907",
pages = "422--425",
booktitle = "Proceedings of SPIE - The International Society for Optical Engineering",
publisher = "Society of Photo-Optical Instrumentation Engineers",

}

TY - GEN

T1 - Photodynamic therapy (PDT) with endoscopic ultrasound for the treatment of esophageal cancer

AU - Woodward, Timothy A.

AU - Wolfsen, Herbert C.

PY - 2000

Y1 - 2000

N2 - In 1995, PDT was approved for palliative use in patients with esophageal cancer. We report our experience using PDT to treat esophageal cancer patients previously treated with combination chemotherapy and radiation therapy. In our series, nine patients referred for PDT with persistent esophageal cancer after chemo-radiation therapy. We found: (1) All patients were men with a mean age of 63 years and eight out of nine had adenocarcinoma with Barrett's esophagus; (2) All patients required endoscopic dilation after PDT; (3) At a mean follow up of 4 months, two T2N0 patients had no demonstrable tumor and all three T3N0 patients had >50% tumor reduction (the partially responsive T3N0 patients will be offered repeat PDT); (4) Patients with metastatic disease (T3N1 or M1) had effective dysphagia palliation. Thus, PDT is safe and effective in ablating all or most tumor in patients with persistent esophageal cancer after chemotherapy and radiation therapy.

AB - In 1995, PDT was approved for palliative use in patients with esophageal cancer. We report our experience using PDT to treat esophageal cancer patients previously treated with combination chemotherapy and radiation therapy. In our series, nine patients referred for PDT with persistent esophageal cancer after chemo-radiation therapy. We found: (1) All patients were men with a mean age of 63 years and eight out of nine had adenocarcinoma with Barrett's esophagus; (2) All patients required endoscopic dilation after PDT; (3) At a mean follow up of 4 months, two T2N0 patients had no demonstrable tumor and all three T3N0 patients had >50% tumor reduction (the partially responsive T3N0 patients will be offered repeat PDT); (4) Patients with metastatic disease (T3N1 or M1) had effective dysphagia palliation. Thus, PDT is safe and effective in ablating all or most tumor in patients with persistent esophageal cancer after chemotherapy and radiation therapy.

UR - http://www.scopus.com/inward/record.url?scp=0033703225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033703225&partnerID=8YFLogxK

M3 - Conference contribution

VL - 3907

SP - 422

EP - 425

BT - Proceedings of SPIE - The International Society for Optical Engineering

PB - Society of Photo-Optical Instrumentation Engineers

ER -